Beijing, Aug 28, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding GLB-005 tablets, developed by Hangzhou Gebo Biopharmaceutical Co., Ltd., to the “Care Program – Extension” pilot for rare disease innovative drug development, targeting transfusion-dependent beta-thalassemia with a public comment deadline of Sept 4, 2026.
Program Snapshot
| Attribute | Detail |
|---|---|
| Program | Care Program – Extension (Rare Disease Innovative Drug Development Incentive Pilot) |
| Product | GLB-005 Tablets |
| Applicant | Hangzhou Gebo Biopharmaceutical Co., Ltd. |
| Indication | Transfusion-dependent beta-thalassemia |
| Comment deadline | Sept 4, 2026 |
| Contact | zhaona@cde.org.cn |
Clinical Context
Transfusion-dependent beta-thalassemia is a rare inherited blood disorder characterized by defective hemoglobin production, requiring lifelong regular blood transfusions and iron chelation therapy. The disease imposes substantial clinical and economic burdens on patients, with limited curative options beyond allogeneic hematopoietic stem cell transplantation, which is constrained by donor availability and transplant risks.
Market Impact Analysis
The inclusion of GLB-005 in the Care Program – Extension signals CDE’s commitment to expanding China’s rare disease pipeline beyond oncology and genetic ophthalmic disorders into hematologic conditions with severe unmet need. Hangzhou Gebo’s focus on transfusion-dependent beta-thalassemia—a disease predominantly prevalent in southern China—positions the asset to address a geographically concentrated patient pool with high clinical urgency.
For the domestic biotech sector, GLB-005’s pilot entry reinforces the viability of the Care Program – Extension as a regulatory fast lane for novel mechanisms in underserved therapeutic areas. The program’s incentive structure—likely encompassing expedited clinical trial consultations, rolling data submissions, and conditional approval pathways—could compress development timelines by 12 to 18 months compared with standard review tracks, provided early-phase data demonstrates meaningful reductions in transfusion burden or improved hemoglobin levels.
The short one-week comment window suggests regulators view the application as non-controversial and aligned with the pilot’s eligibility criteria, potentially clearing the way for formal inclusion by mid-September 2026.
Forward-Looking Statement
Industry analysts expect GLB-005 to advance rapidly into clinical trials under the pilot’s enhanced regulatory support framework, with Phase I/II initiation possible by early 2027 if pharmacology and toxicology packages are complete. Success in beta-thalassemia could open broader indications within the hemoglobinopathies spectrum, including sickle cell disease variants prevalent in China’s southern provinces. The pilot’s backing of GLB-005 also underscores Beijing’s strategic emphasis on reducing reliance on imported orphan drugs for blood disorders, creating a favorable policy environment for domestic developers with gene therapy, small-molecule, or protein-based approaches to thalassemia. Final pilot inclusion is anticipated following the Sept 4 comment deadline, barring substantive objections.-China Health Reform Pulse
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/67a5e0012e1365506db4e423b6c9ba52